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Background: Treatment adherence is crucial in patients with cystic fibrosis, but poor adherence 
is a problem, especially during adolescence. Identification of barriers to treatment adherence 
and a better understanding of how context shapes barriers is of great importance in the disease. 
Adolescent reports of barriers to adherence have been studied, but studies of their parents’ 
experience of such barriers have not yet been carried out. The aim of the present study was to 
explore barriers to treatment adherence identified by young patients with cystic fibrosis and 
by their parents.
Methods: A questionnaire survey of a cohort of young Danish patients with cystic fibrosis 
aged 14–25 years and their parents was undertaken.
Results: Barriers to treatment adherence were reported by 60% of the patients and by 62% of 
their parents. Patients and parents agreed that the three most common barriers encountered were 
lack of time, forgetfulness, and unwillingness to take medication in public. We found a significant 
positive correlation between reported number of barriers and perceived treatment burden. We 
also found a statistically significant relationship between the reported number of barriers and 
treatment adherence. A significant association was found between the number of barriers and 
the reactions of adolescents/young adults and those of their mothers and fathers, and between 
the number of barriers and the way the family communicated about cystic fibrosis.
Conclusion: The present study showed that the majority of adolescents with cystic fibrosis 
and their parents experienced barriers to treatment adherence. Agreement between adolescents 
and their parents regarding the level and types of barriers indicates an opportunity for close 
cooperation between adolescents, their parents, and health care professionals in overcoming 
adolescent adherence problems.
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Introduction
Cystic fibrosis is a chronic, progressive, and life-limiting disease that requires daily 
medical treatment, including physiotherapy and oral and inhaled respiratory medication 
to minimize deterioration of lung function, and dietary supplementation with pancreatic 
enzymes and vitamin supplements to prevent malabsorption. Medical treatment for 
cystic fibrosis is demanding, and adherence to medical treatment is crucial, because 
poor adherence may imply poor health outcomes.1,2 However, poor adherence is 
notably a problem, especially during adolescence.3,4 Rates of adherence to treatment 
for cystic fibrosis are generally low, and vary depending on the type of treatment,3,5,6 
age and gender of the patient,4,7 and method of assessment.8
Several studies have explored the etiology of nonadherence, eg, nonadherence 
to chest physiotherapy as a result of perceived therapeutic ineffectiveness,9 prob-Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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lems with fitting chest physiotherapy into lifestyle, and the 
physical consequences of chest physiotherapy.10 The family 
and atmosphere in the family also seems to be important. An 
American study suggests that older children and adolescents 
who come from families experiencing unhappy and conflicted 
relationships may be at greater risk of poor adherence to 
treatment.11   Furthermore, higher levels of family cohesion 
and families with a greater balance between cohesion and 
flexibility seem to show higher rates of both child-reported 
and parent-reported adherence.12
During the past few years, self-reported barriers to treat-
ment adherence have attracted growing interest. Identifying 
barriers to adherence and factors in the family as potential 
barriers to adherence may be of great importance for address-
ing adherence problems.
The purpose of an American study of children with cystic 
fibrosis and asthma was to systematically identify barriers 
to treatment adherence by asking children and their parents 
about adherence. The investigators found that some of the 
barriers were the same for the two diseases, whereas others 
were disease-specific.13 However, this study only included 
children. Barrier scales have been developed and validated 
for adolescents with other diseases.14,15 Two recent studies 
in the area of cystic fibrosis aimed to identify barriers to 
adherence experienced by adolescents.16,17 Interviews with 
adolescents and young adults with cystic fibrosis revealed 
treatment burden as the most frequently noted barrier,16 while 
a questionnaire study of adolescents with cystic fibrosis found 
forgetting and time management to be the most frequent barri-
ers to adherence.17 However, these studies of adolescents with 
cystic fibrosis did not include the points of view of parents.
The aim of the present study was to explore barriers to 
treatment perceived by adolescent patients with cystic fibrosis 
and their parents, and the context in which such barriers arise, 
with a view to developing strategies to improve adherence. 
We hypothesized that adolescents and their mothers and 
fathers would agree upon the level and types of barriers to 
adherence. Additionally, we hypothesized that a high treat-
ment burden as well as conflicts in the family induce greater 
barriers to treatment adherence.
Materials and methods
Participants and procedures
Danish patients aged 14–25 years with a confirmed diagnosis 
of cystic fibrosis (n = 146) and their parents (n = 269) formed 
the target group, and were identified from the Danish Cystic 
Fibrosis Registry. They were introduced to the study by a 
mailed letter, and data were collected through web-based 
questionnaires from February 2010 to June 2010.   Adolescent 
and young adult patients are referred to as adolescents in 
this paper.
Questionnaires
This investigation was part of a larger exploratory study in 
which focus groups and individual interviews were conducted 
to identify areas of concern. Two focus group interviews 
with adolescents were conducted, comprising one for ado-
lescents aged 14–18 years (n = 7) and another for those aged 
19–25 years (n = 6), and three individual interviews were 
conducted with severely ill patients. We sought an equal dis-
tribution with regard to gender, age, and disease severity as 
measured by lung function (forced expiratory volume in one 
second as percent of predicted [FEV1%]). One focus group 
interview (n = 5) and two individual interviews were con-
ducted with the parents. Here we sought an equal distribution 
with regard to gender, child’s gender, age, and disease severity. 
The key question was, “What can the cystic fibrosis centre do 
to support the adolescent with cystic fibrosis in the successful 
transition into adult life? – in the areas of (1) managing the 
disease in everyday life, (2) balancing between adherence 
and autonomy, (3) risky behavior and (4) in relation to the 
parents?” (the last question being for patients only). Analysis 
of these interviews identified several themes, ie, adherence 
and issues that may influence adherence, cooperation with 
parents, cooperation with the cystic fibrosis center, and risky 
behavior. On the basis of these themes, several questionnaires 
covering these themes were developed. In this study, we report 
the results concerning adherence issues only.
Barriers to adherence emerged as a prominent theme dur-
ing the interviews, so a “barriers to adherence” questionnaire 
was designed. Adolescent adherence was explored using a 
separate questionnaire. To explore family matters relevant to 
adolescent barriers to adherence, four additional question-
naires addressing reactions of the mother, reactions of the 
father, reactions of the adolescent, and communication about 
cystic fibrosis within the family were developed, also on the 
basis of the interviews. The questionnaire about barriers to 
adherence contained five questions exploring why the adoles-
cent did not take the medication as recommended (Table 1). A 
Likert scale had four response options, ie, “absolutely right” to 
“absolutely wrong” and the option “do not know”. The “adher-
ence” questionnaire had seven questions on adherence to the 
recommended daily as well as intermittent medical treatment 
(Table 1). Here it should be noted that the recommended kind 
of chest physiotherapy for Danish patients with cystic fibrosis 
is a positive expiratory pressure mask. A Likert scale with six Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Table 1 The six questionnaires with internal consistencies (Cronbach’s alpha) and test-retest Spearman’s correlation
Item Items (n) Adolescent  
Cronbach’s α
Parent  
Cronbach’s α
Adolescent test-retest  
Spearman’s  
correlation
Parent test-retest 
Spearman’s 
correlation
Barriers to adherence 5 0.76 0.82 0.84 0.81
Difficulty finding time to take CF treatment
Forgetting to take cF treatment
choose to be with friends instead  
of taking cF treatment
Too tired to take cF treatment
Will not take cF treatment in public
Adherence during past month 7 0.73 0.88 0.95 0.86
Antibiotic tablets
Pulmozyme®
Positive expiratory pressure mask
enzymes
Vitamins
Asthma medication
inhaled antibiotics
Reactions from mother 8 0.82 0.75
Reactions from father 8 0.91 0.64
says you are good at remembering treatment
scolds you for forgetting treatment
Asks you to take your treatment although  
you are doing something else
Quarrels with you about treatment
Praises your effort to take your treatment
helps you only when you ask for help
checks that you have taken your treatment
Trusts that you have taken your treatment
Reactions from adolescent 5 0.91 0.79
get annoyed when parents ask me to take  
treatment
Tell my parents that i appreciate their help
get sullen when my parents ask me to take  
treatment
Ask parents to mind their own business
Quarrel with parents about treatment
Communication about CF in family 6 0.90 0.83
We communicate openly about cF
We are good at supporting each other  
when cF takes up all the time
We can express our feelings towards  
each other regarding cF
We can talk about everything concerning cF
We can talk about our anxiety concerning cF
We can communicate about cF although  
we are depressed
Abbreviation: CF, cystic fibrosis.
response options ranging from “taken the treatment every 
day” to “missed the treatment every day” and the option “does 
not get this treatment” was available. We defined three levels 
of adherence, ie, high adherence (“missed the treatment no 
more than once during the past month”), medium adherence 
(“missed the treatment no more than once a week”), and low 
adherence (“missed the treatment more than once a week”). 
The questionnaires exploring the reactions of mothers, fathers, 
and adolescents contained eight questions (Table 1) and a four-
option Likert scale featuring response options from “daily” to 
“never” and a “not relevant” option. The questionnaire about 
family communication and support contained six questions 
(Table 1). We used a four-option Likert scale with response 
categories from “strongly agree” to “strongly disagree”.   Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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We considered the answers “do not know”, “does not get this 
treatment”, and “not relevant” as missing items and substituted 
them with the mean of the other items.
We consulted multidisciplinary specialist staff and rel-
evant literature to evaluate the relevance of the questions. The 
questionnaires were pilot-tested in two Danish cystic fibrosis 
centers (adolescents n = 9, parents n = 6) to evaluate if the 
questions were intelligible and relevant.
The internal reliability of each questionnaire was cal-
culated using Cronbach’s alpha to assess the association 
between the items and the questionnaires (Table 1). Items 
with a Cronbach’s alpha below the recommended 0.7 mini-
mum level18 were deleted. Other items were deleted for 
theoretical reasons, eg, items that proved to be obscure when 
looking at the answers.
Test-retest reliability was tested 10–23 days later in a 
group of patients (n = 24) and a group of parents (n = 61) 
using   Spearman’s correlation (Table 1). The purpose was to 
assess the stability of the scores over time, and a correlation 
higher than 0.80 suggested adequate stability.19 A paired 
t-test was conducted to measure the difference between the 
test and the retest to ensure that a correlation was not due to 
a systematic error.
Other measures
Forced expiratory volume in one second as a percent of 
predicted (FEV1%) and body mass index were included as 
measures of health status. These data were extracted from 
the National Cystic Fibrosis Registry, and an average of the 
measures from 2009 was used. The Danish version of the 
Revised Cystic Fibrosis Quality of Life Questionnaire in 
adolescents and adults (CFQ-R) was included as a measure 
of quality of life.20
ethical considerations
The study was registered with the Danish Data Agency Board. 
According to Danish law, no particular ethical permission is 
needed to conduct a study that does not include biomedical 
aspects, and written consent from the participants is not 
needed in web-based questionnaire studies. Psychologists, 
doctors, and nurses at the cystic fibrosis centers were avail-
able for psychological support and treatment of patients, if 
needed. However, no such need was observed.
statistical analysis
Descriptive statistics were performed to describe participant 
demographics, the types and numbers of barriers to 
  adherence, and adherence subgroups. Chi-square tests and 
Mann-Whitney U tests were used to determine if differences 
between participants and nonparticipants and between 
participants and retest-participants were statistically 
significant. Adolescent reports of ”barriers to adherence” 
were paired and compared with their mothers’ and their 
fathers’ reports of adolescent “barriers to adherence” using 
the Wilcoxon signed-rank test. The adolescents were divided 
into two groups, ie, those with one or more barriers to adher-
ence (answered absolutely right or right) and those with 
no barriers to adherence (answered “absolutely wrong”, 
“wrong”, or “do not know”) in order to compare the two 
groups.
Spearman’s rank order correlation was conducted to 
examine the association between barriers to adherence and 
adherence, reactions from mother, father, and the adolescent, 
communication about cystic fibrosis, age, body mass index, 
FEV1%, and quality of life subscales. No Type I error cor-
rections were made because correlations between most of 
the variables were expected. The Mann-Whitney U test was 
performed to compare reactions and communication in the 
family for the barrier group with those for the no-barrier 
group.
Results
Participants
The questionnaires were completed by 60% (n = 88) of the 
adolescents and 62% (n = 161) of the parents. A total of 
68% (n = 93) of the mothers and 54% (n = 68) of the fathers 
completed the questionnaires, with a total of 72 child-mother 
dyads, 57 child-father dyads, and 60 mother-father dyads. 
Participant characteristics are shown in Table 2.
The participating adolescents had a statistically signifi-
cant higher FEV1% than the nonparticipating adolescents, 
and females were significantly more numerous among the 
participating adolescents, as well as parents than among 
nonparticipating adolescents and parents (Table 2). The 
retest participants did not differ significantly from the 
participants regarding gender, age, body mass index, and 
FEV1% (Table 2).
reliability and validity
Cronbach’s alpha coefficients ranged from 0.73 to 0.91 
(Table 1). Test-retest reliability ranged from 0.64 to 0.95 
(Table 1). A paired t-test showed no significant difference 
between the scores in the test and the retest. Content validity, 
including item coverage, relevance, and face validity of the 
questionnaires, was validated by experts in cystic fibrosis and 
adolescence several times during the process of developing Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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the questionnaires. The final versions were considered to be 
good according to the expert panels, patients, and results of 
pilot testing.
Barriers to adherence
Most of the adolescents (61%, n = 54) reported having one or 
more adherence barriers. Their experience was acknowledged 
by most of the mothers (59%, n = 54) and fathers (60%, 
n = 40). The types and frequencies of barriers to adherence 
are shown in Table 3. The adolescents and their mothers and 
fathers agreed that the three most common barriers were lack 
of time, forgetfulness, and unwillingness to take treatment 
in public (Table 3). Wilcoxon signed-rank tests for the child-
mother (P = 0.75), child-father (P = 0.72), and mother-father 
(P = 0.73) dyads showed no statistically significant differ-
ences in their reports of number of adherence barriers.
Adolescent reports of barriers to adherence correlated 
significantly at the 0.001 level with adherence and treatment 
burden (Table 4). Significant correlations were also found 
for most of the other parameters (Table 4). No significant 
correlation with age was found.
Adolescent adherence varied with the kind of treatment, 
but in this study we only reported overall adherence. Overall, 
Table 2 characteristics of participants, nonparticipants, and re-test participants
Participants Nonparticipants Significance (two-tailed) Retest participants
Adolescents (n) 88 58 24
Male/female (%)a 40/60 64/36 0.008c 29/71
Age (mean ± SD)b 19.3 ± 3.2 18.7 ± 3.5 0.217 19.9 ± 3.6
FeV1% (mean ± SD)b 82.6 ± 22.7 74.8 ± 22.5 0.046c 77.9 ± 20.8
BMI (mean ± SD)b 20.6 ± 3.6 19.9 ± 2.4 0.381 20.5 ± 4.4
Parents (n) 161 108 61
Male/female (%)a 42/58 57/43 0.023c 38/62
Child’s FEV1% (mean ± SD)b 81.5 ± 22.9 76.3 ± 23.3 0.082 82.1 ± 21.9
Notes: aPearson Chi-square; bindependent-samples Mann-Whitney U test; csignificant at 0.05 level (two-tailed). 
Abbreviations: BMi, body mass index; FeV1%, forced expiratory volume in one second as percent of predicted; SD, standard deviation.
Table 3 Frequency data for adolescent and parental reports of 
type and number of barriers to adherence
Adolescent  
reports %  
(n)
Mothers’  
reports %  
(n)
Fathers’  
reports %   
(n)
Types of barriers
Difficult to find time  
to take cF treatment
40 (35) 29 (27) 31 (21)
Forget to take cF  
treatment
40 (35) 36 (33) 21 (14)
choose to be with  
friends instead of  
taking cF treatment
25 (22) 24 (22) 16 (11)
Too tired to take  
cF treatment
25 (22) 27 (25) 19 (13)
Will not take cF  
treatment in public
33 (29) 28 (26) 37 (25)
Number of barriers
0 barrier 39 (34) 41 (38) 40 (27)
1 barrier 17 (15) 20 (18) 27 (18)
2 barriers 14 (12) 15 (14) 15 (10)
3 barriers 11 (10) 7 (6) 6 (4)
4 barriers 12 (11) 12 (11) 9 (6)
5 barriers 7 (6) 5 (5) 3 (2)
Abbreviation: CF, cystic fibrosis.
Table 4 correlations between barriers to adherence and adher-
ence, reactions from mother, reactions from father, reactions from 
adolescent, communication about cF in family, age, BMi, FeV1, and 
cFQ measures
Spearman’s  
correlation
Significance value 
(two-tailed)
Adherence 0.54 0.001a
reactions from mother 0.26 0.016a
reactions from father 0.28 0.021a
reactions from adolescent 0.31 0.008a
communication about  
cF in family
0.26 0.016a
Age -0.03 0.784
BMi 0.22 0.040a
FeV1% average of 2009 measures 0.15 0.164
CF-related quality of life (CFQ)
Physical functioning -0.07 0.551
role limitations -0.23 0.030a
Vitality -0.17 0.127
emotional functioning -0.25 0.020a
social functioning -0.15 0.169
Body image -0.05 0.638
eating disturbances -0.05 0.670
Treatment burden -0.38 0.001a
health perceptions -0.12 0.260
Weight problems 0.04 0.694
respiratory symptoms -0.31 0.004a
Digestive symptoms -0.28 0.009a
Note: aSignificant at 0.05 level (two-tailed). 
Abbreviations: BMi, body mass index; FeV1%, forced expiratory volume in one 
second as percent of predicted; CF, cystic fibrosis; CFQ, Cystic Fibrosis Quality of 
Life Questionnaire.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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the adolescents reported lower adherence than their parents 
did, and those with barriers to adherence reported lower 
adherence than those with no barriers (Table 5).
Looking at single items in the questionnaires about 
reactions from mother, father, and adolescent, quarrels and 
negative reactions were significantly more often reported 
by the adolescents encountering adherence barriers than 
by adolescents reporting no barriers (Table 6). Likewise, 
support and positive communication about cystic fibrosis in 
the family were significantly more infrequently reported by 
adolescents with adherence barriers than by those reporting 
no barriers (Table 6).
Discussion
Barriers to treatment adherence were reported by 60% of 
adolescents and by 62% of their parents. In other studies, 
adolescents reported lower rates,17 similar rates,16 or even 
higher rates.13 The discrepancy between the extent to which 
barriers are reported in these studies may be attributable 
to methodological differences. A study comparing reports 
by children with those of their parents showed higher rates 
reported by parents than by children. However, the unanim-
ity between the adolescents’ and parents’ evaluation in the 
present study is seen as a strength.
The adolescents and their mothers and fathers also 
agreed that the three most common barriers were lack of 
time, forgetfulness, and unwillingness to take medication 
in public. This finding resonates with adolescent reports in 
other studies,15,17 but until now, no reports of parental experi-
ence of level and type of barriers have been available. Time 
management and forgetfulness were also among the most 
frequent adherence barriers in children with cystic fibrosis 
and their parents, although oppositional behaviors, taste, and 
swallowing also seemed to be frequent barriers in those aged 
6–13 years.13 In adolescents, other studies have reported that 
fatigue and a preference for being with friends instead of tak-
ing medication are also common adherence barriers.16 The 
convergence of the types of barriers was convincing. Thus, 
the present study adds new information to the existing knowl-
edge by showing parental awareness of adolescent barriers 
to   treatment   adherence. This may give health professionals 
good   opportunities for collaborating with adolescents and 
their parents to improve adherence.
Treatment burden was found to have a significant 
positive correlation with the number of barriers, which 
is consistent with a recent study in adolescents.16 A high 
level of polypharmacy is thus problematic from the patient 
perspective. This demands that physicians carefully weigh 
up the pros and cons in cooperation with the patient before 
prescribing any additional treatment. The patient is the most 
obvious person to estimate if an additional treatment can fit 
in with his or her life. As suggested in another study, health 
care professionals need to understand not only what is the 
optimal objective medical condition, but they also need to 
develop an insight into the subjective experience of living 
with cystic fibrosis.21
The adolescents reported lower adherence than did their 
parents, whereas other research has shown that adolescents 
and parents report equal adherence levels.12 This discrepancy 
may be rooted in the subjective and potentially inaccurate 
nature of self-reported adherence. Furthermore, adolescents 
may be more accurate reporters than their parents, who 
may not be fully aware of the adolescent’s adherence level. 
  Adolescents encountering barriers reported lower adher-
ence that those who did not, and a statistically significant 
relationship was found between adherence and the number 
of barriers. These findings confirm those of other studies.13 
Identifying adherence barriers and finding solutions to over-
come these barriers is important for disease management. The 
solutions may involve discussion with the adolescent patient 
about adherence issues and the consequences of nonadherence 
to establish a workable compromise, as recently   suggested.22 
Discussions may also be initiated on how to prioritize 
treatment to avoid a situation whereby the adolescent either 
accepts all treatment or rejects all treatment because of being 
overwhelmed by lack of time or energy.
A higher number of barriers seemed to correlate with 
lower body mass index and more digestive and respiratory 
symptoms. Predictably, the more barriers to adherence, 
the lower the adherence, and the lower the adherence, the 
Table 5 Frequency data for adolescent and parental reports of adolescent adherence
Report from n High adherence Medium adherence Low adherence
Adolescents (all) 88 42% 43% 15%
Parents 137 59% 32% 9%
Adolescents with one or more barriers to adherence 54 26% 56% 18%
Adolescents with no barriers to adherence 34 68% 23% 9%Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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lower the body mass index and the greater the digestive and 
  respiratory symptoms. In reality, we are facing an association, 
but do not know what is cause and what is effect.
The significant associations between number of   barriers 
and reactions from the mother, father, and adolescent and 
communication about cystic fibrosis in the family are 
consistent with findings at the single-item level (Table 6), 
showing that adolescents facing adherence barriers appar-
ently had more quarrels with their parents and that these 
families were less likely to support one another. This cor-
relates with other studies that found positive family factors 
to correlate with increased adherence.11 These findings are 
most interesting because they suggest that relationships 
and atmosphere within the family may partly shape the 
adolescent patient’s perception of barriers to adherence 
and adherence itself.
A limitation of the present study is that the groups 
were not fully comparable. Participating adolescents had 
a statistically significantly higher FEV1% than the non-
participating adolescents, and the participants included 
significantly more females than did the nonparticipants. 
Thus, bias may have arisen because patients with mild 
disease are more prone than patients with severe disease 
to participate in surveys, as are females compared with 
males. Use of web-based questionnaires may also be 
considered a limitation although, to our knowledge, no 
Table 6 Comparison of mean item scores from the questionnaires exploring reactions from mother, father, and adolescent, and family 
communication about cF in the barrier group and the no-barrier group
n Adolescents with  
barriers mean (SD)
Adolescents with no  
barriers mean (SD)
Mann-Whitney U  
test significance
Reactions from mothera
says you are good at remembering treatment 70 3.33 (0.80) 2.80 (0.91) 0.014c
scolds you for forgetting treatment 75 1.82 (0.91) 1.46 (0.78) 0.069
Asks you to take your treatment although  
you are doing something else
72 2.17 (1.17) 2.20 (1.15) 0.906
Quarrels with you about treatment 76 1.60 (0.73) 1.15 (0.37) 0.006c
Praises your effort to take treatment 69 3.22 (0.81) 3.00 (0.95) 0.392
helps you only when you ask for help 63 2.77 (1.03) 2.22 (1.08) 0.042c
checks that you have taken your treatment 76 2.31 (1.29) 2.32 (1.28) 0.950
Trusts that you have taken your treatment 77 1.65 (0.55) 1.18 (0.99) 0.015c
Reactions from fathera
says you are good at remembering treatment 59 3.50 (0.70) 2.83 (0.94) 0.004c
scolds you for forgetting treatment 58 1.46 (0.60) 1.32 (0.48) 0.423
Asks you to take your treatment although  
you are doing something else
59 1.57 (0.90) 1.95 (1.21) 0.263
Quarrels with you about treatment 62 1.35 (0.48) 1.09 (0.29) 0.027c
Praises your effort to take treatment 59 3.49 (0.65) 2.82 (0.91) 0.004c
helps you only when you ask for help 56 3.09 (0.88) 2.30 (1.02) 0.004c
checks that you have taken your treatment 61 1.84 (1.00) 1.96 (1.15) 0.860
Trusts that you have taken your treatment 65 1.78 (1.12) 1.28 (0.79) 0.034c
Reactions from adolescenta
get annoyed when parents ask me to take treatment 62 2.51 (1.12) 2.04 (0.93) 0.111
Tell parents that i appreciate their help 64 3.43 (0.71) 3.29 (0.75) 0.467
get sullen when parents ask me to take treatment 65 2.31 (1.07) 1.61 (0.66) 0.010c
Ask parents to mind their own business 66 1.74 (0.88) 1.09 (0.29) 0.001c
Quarrel with parents about treatment 66 1.80 (0.88) 1.21 (0.41) 0.003c
Communication about CF in familyb
We communicate openly about cF 88 1.30 (0.57) 1.15 (0.36) 0.205
We are good at supporting each other when cF takes up time 88 1.65 (0.85) 1.29 (0.52) 0.044c
We can express our feelings towards each other regarding cF 88 1.93 (0.89) 1.53 (0.71) 0.034c
We can talk about everything concerning cF 88 1.63 (0.85) 1.35 (0.54) 0.188
We can talk about our anxiety concerning cF 88 1.70 (0.90) 1.47 (0.56) 0.421
We can communicate about cF even if we are depressed 88 1.83 (0.93) 1.41 (0.56) 0.040c
Notes: aLikert scale (1 = daily, 2 = weekly, 3 = monthly, 4 = never); bLikert scale (1 = strongly agree, 2 = agree, 3 = disagree, 4 = strongly disagree); cSignificant at 0.05 level 
(two-tailed). 
Abbreviations: CF, cystic fibrosis; SD, standard deviation.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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adolescents and only one parent did not have access to the 
Internet. Another limitation is the mean substitution of the 
answers “do not know”, “does not get this treatment”, and 
“not relevant”, because several studies have shown that lev-
els of adherence vary according to the type of treatment.23 
Moreover, self-reporting involves a subjective element, 
and an objective electronic measure would have yielded 
more reliable data.23 It may also be argued that correction 
for Type I error should have been included because of the 
multiple correlations. However, we found correlations with-
out correction for Type 1 errors to be appropriate because 
the comparisons were actually expected and not performed 
just to see what might appear.24 The present study reports 
patient-related and treatment-related barriers, and hence 
does not take patient-provider factors into account, even 
if they may play a role, as suggested in organ transplant 
research.25 Differences in the methods used to measure 
barriers to adherence hinder any comparison of outcomes. 
Another limitation is the lack of use of validated measures. 
Barrier scales have been developed and validated for 
adolescents with other diseases14,15 but, to our knowledge, 
not yet for adolescents with cystic fibrosis. This would be 
instrumental in furthering our understanding of adherence 
issues in this patient group.
Conclusion
Treatment adherence is crucial to patients with cystic 
fibrosis. This exploratory study showed that the majority 
of adolescents with cystic fibrosis and their parents expe-
rienced barriers to treatment adherence. The agreement 
between adolescents and their parents regarding the level 
and types of barriers that exist affords an opportunity for 
close cooperation between adolescents, their parents, and 
health care professionals in overcoming adherence   problems. 
Further research is needed to unearth the etiology of 
poor adherence and to design effective intervention to 
improve adherence.
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